TopFunds

Cardinal Health

NYSE: CAH

Stock price

238.96 USD

(+390.58%) 5 years

Health Care DistributorsMedical - Distribution

Financial Performance

Share

5Y price score: 508

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 238.4%

DATE RANGE:

%

ㅤ

  • Earnings per share

  • Free cash flow per share

  • Stock price

Time scale:

By default your notes are visible only to you.

151.8

52-week range

258.3

238.96

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

8 %

Dividend Yield TTM

0.9 %

Market cap $

$ 55,966

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

33.1

Price / Book TTM

(19.6)

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

2.7

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

53.1 %

412 %

238.4 %

Free cash flow per share growth

11.7 %

176.7 %

151.4 %

Earnings per share growth

69 %

247.6 %

67.4 %

Founded: 1,971

Employees: 57,700

Business Summary:Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.

Q&A

SEARCH
Get answers on financials, industry, fundamentals or other questions.

Contribute

By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more

VIEW ALL Q&A

Contribute or ask questions about business following TopFunds community guidelines

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2026 Q4 (Aug 11, 2026)

1) Strategy & Leadership
- Cardinal Health concluded fiscal year 2026 with strong execution and broad-based performance, particularly in Pharmaceutical and Specialty Solutions.
- The company emphasized its commitment to operational excellence and strategic long-term investments, positioning for growth in fiscal 2027 and beyond.
- CEO Jason Hollar highlighted the importance of simplifying operations and enhancing customer service capabilities through investments in automation and technology.

2) Financial & Segment Results
- Total revenue for Q4 2026 was $63.7 billion, a 6% increase YoY, with operating earnings growing 30% and EPS increasing 40% to $2.91.
- The Pharmaceutical segment revenue grew 6% to $58.8 billion, with segment profit increasing 21% to $645 million, driven by strong demand and brand-to-generic conversions.
- The Global Medical Products and Distribution (GMPD) segment reported a 2% decline in revenue to $3.1 billion, impacted by tariff-related payables, but profit increased to $150 million, aided by a one-time $100 million tariff refund.
- Other growth businesses generated $1.7 billion in revenue (7% growth) and $183 million in profit (14% growth).

3) Problems / Headwinds
- The company faced headwinds from IRA WACC changes, which impacted revenue growth in the Pharmaceutical segment, estimated at around 500 basis points.
- GMPD experienced a decline in revenue due to expected payables related to tariff refunds and lower distribution volumes, although the underlying operational performance showed improvement.
- Rising input costs, particularly in oil and petroleum products, are being monitored closely, with potential impacts on profitability if they remain elevated.

4) Operational or Product Plans
- Cardinal Health is focused on expanding its Specialty business and enhancing its capabilities in biopharma solutions, with plans to support innovative therapies entering the market.
- The company is investing in automation and technology to drive efficiencies and improve service levels, particularly in its at-home solutions and logistics businesses.
- Strategic acquisitions, such as the recent purchase of Strive Medical and the Diabetes Health segment of AdaptHealth, are expected to contribute to growth and operational synergies.

5) Guidance & Outlook / Investor Angle
- For fiscal year 2027, Cardinal Health is guiding for EPS growth of 13% to 15%, with expected revenue growth of 3% to 5% in the Pharmaceutical segment and 2% to 4% in GMPD.
- The company aims to generate $3.5 billion to $4 billion in adjusted free cash flow, maintaining a disciplined capital allocation strategy with a focus on returning capital to shareholders, including a $1 billion share repurchase program.
- Long-term EPS growth guidance remains at 12% to 14% per year, reflecting confidence in the business's growth trajectory and balance sheet strength.

Bottom line: Cardinal Health's strong performance in fiscal 2026, driven by robust demand and strategic investments, positions the company well for continued growth in fiscal 2027, with a focus on enhancing operational efficiencies and returning capital to shareholders.

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20262025202420232022202120202019201820172016

Cardinal Health — Financial Overview, Stock Price, Market Cap

Cardinal Health is a company. Founded in 1971. As of October 9, 2026, the company's market capitalization is $55965865760 with a current stock price of $238.96.